{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:56:52Z","timestamp":1787003812031,"version":"build-2736575974"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-88374-w","type":"journal-article","created":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T04:26:11Z","timestamp":1738643171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single inhaler with beclometasone, formoterol, and glycopyrronium versus triple therapies in adults with uncontrolled asthma: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2460-4709","authenticated-orcid":false,"given":"Fulvio","family":"Braido","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9306-3750","authenticated-orcid":false,"given":"Ioanna","family":"Vlachaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9008-6896","authenticated-orcid":false,"given":"Georgios F.","family":"Nikolaidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6524-9048","authenticated-orcid":false,"given":"Dimitrios","family":"Tzelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-9570","authenticated-orcid":false,"given":"Ifigeneia","family":"Barouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8029-2159","authenticated-orcid":false,"given":"Alessio","family":"Piraino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6794-9127","authenticated-orcid":false,"given":"Alessandra","family":"Madoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6400-6573","authenticated-orcid":false,"given":"Nicola","family":"Scichilone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,4]]},"reference":[{"key":"88374_CR1","unstructured":"Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. (2023)."},{"key":"88374_CR2","doi-asserted-by":"publisher","first-page":"04052","DOI":"10.7189\/jogh.12.04052","volume":"12","author":"P Song","year":"2022","unstructured":"Song, P., et al. Global, regional, and national prevalence of asthma in 2019: A systematic analysis and modelling study. J. Glob. Health 12, 04052 (2022).","journal-title":"J Glob Health"},{"key":"88374_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1185\/03007995.2014.1001062","volume":"31","author":"LM Graham","year":"2015","unstructured":"Graham, L.M. & Eid, N. The impact of asthma exacerbations and preventive strategies. Curr. Med. Res. Opin. 31, 825\u2013835 (2015).","journal-title":"Curr Med Res Opin"},{"key":"88374_CR4","unstructured":"National Institute for Health and Care Excellence (NICE). Asthma: Diagnosis, Monitoring and Chronic Asthma Management NICE Guideline. (2017)."},{"key":"88374_CR5","doi-asserted-by":"crossref","unstructured":"Cloutier, M.M., et al. 2020 Focused updates to the asthma management guidelines: A report from the national asthma education and prevention program coordinating committee expert panel working group. J. Allergy Clin. Immunol. 146, 1217\u20131270 (2020).","DOI":"10.1016\/j.jaci.2020.10.003"},{"key":"88374_CR6","unstructured":"British Thoracic Society. SIGN158 British guideline on the management of asthma. (ed. Network, S.I.G.) (2019)."},{"key":"88374_CR7","doi-asserted-by":"crossref","unstructured":"Buels, K.S. & Fryer, A.D. Muscarinic receptor antagonists: effects on pulmonary function. Handb. Exp. Pharmacol., 317\u2013341 (2012).","DOI":"10.1007\/978-3-642-23274-9_14"},{"key":"88374_CR8","doi-asserted-by":"publisher","first-page":"100007","DOI":"10.1016\/j.waojou.2018.12.001","volume":"12","author":"GW Canonica","year":"2019","unstructured":"Canonica, G.W., et al. Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the severe Asthma Network in Italy (SANI) registry. World Allergy Organ. J. 12, 100007 (2019).","journal-title":"World Allergy Organ J"},{"key":"88374_CR9","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1016\/j.jaci.2015.07.046","volume":"136","author":"P Lefebvre","year":"2015","unstructured":"Lefebvre, P., et al. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma. J. Allergy Clin. Immunol. 136, 1488\u20131495 (2015).","journal-title":"J Allergy Clin Immunol"},{"key":"88374_CR10","doi-asserted-by":"publisher","first-page":"j1415","DOI":"10.1136\/bmj.j1415","volume":"357","author":"AK Waljee","year":"2017","unstructured":"Waljee, A.K., et al. Short term use of oral corticosteroids and related harms among adults in the United States: Population based cohort study. BMJ 357, j1415 (2017).","journal-title":"BMJ"},{"key":"88374_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.anai.2019.01.018","volume":"122","author":"WC Anderson","year":"2019","unstructured":"Anderson, W.C., 3rd & Szefler, S.J. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic? Ann. Allergy Asthma Immunol. 122, 367\u2013372 (2019).","journal-title":"Ann Allergy Asthma Immunol"},{"key":"88374_CR12","doi-asserted-by":"crossref","unstructured":"Ciprandi, G., Marseglia, G.L., Ricciardolo, F.L.M. & Tosca, M.A. Pragmatic markers in the management of Asthma: A real-world-based Approach. Children (Basel) 7, (2020).","DOI":"10.3390\/children7050048"},{"key":"88374_CR13","doi-asserted-by":"publisher","first-page":"106021","DOI":"10.1016\/j.rmed.2020.106021","volume":"170","author":"C Gessner","year":"2020","unstructured":"Gessner, C., et al. Fixed-dose combination of indacaterol\/glycopyrronium\/mometasone furoate once-daily versus salmeterol\/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, phase IIIb, non-inferiority study (ARGON). Respir. Med. 170, 106021 (2020).","journal-title":"Respir Med"},{"key":"88374_CR14","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","volume":"8","author":"HAM Kerstjens","year":"2020","unstructured":"Kerstjens, H.A.M., et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): A randomised, double-blind, controlled phase 3 study. Lancet Respir. Med. 8, 1000\u20131012 (2020).","journal-title":"Lancet Respir Med"},{"key":"88374_CR15","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","volume":"9","author":"LA Lee","year":"2021","unstructured":"Lee, L.A., et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): A double-blind, randomised, phase 3A trial. Lancet Respir. Med. 9, 69\u201384 (2021).","journal-title":"Lancet Respir Med"},{"key":"88374_CR16","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","volume":"394","author":"JC Virchow","year":"2019","unstructured":"Virchow, J.C., et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): Two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet 394, 1737\u20131749 (2019).","journal-title":"Lancet"},{"key":"88374_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ejim.2021.01.027","volume":"85","author":"A Papi","year":"2021","unstructured":"Papi, A., et al. Inhaled long-acting muscarinic antagonists in asthma\u2212a narrative review. Eur. J. Intern. Med. 85, 14\u201322 (2021).","journal-title":"Eur J Intern Med"},{"key":"88374_CR18","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1001\/jama.2021.7872","volume":"325","author":"LHY Kim","year":"2021","unstructured":"Kim, L.H.Y., Saleh, C., Whalen-Browne, A., O\u2019Byrne, P.M. & Chu, D.K. Triple vs dual inhaler therapy and asthma outcomes in moderate to severe asthma: A systematic review and Meta-analysis. JAMA, 325, 2466\u20132479 (2021).","journal-title":"JAMA"},{"key":"88374_CR19","doi-asserted-by":"crossref","unstructured":"Rogliani, P., Ritondo, B.L. & Calzetta, L. Triple therapy in uncontrolled asthma: A network meta-analysis of phase III studies. Eur. Respir. J. 58, (2021).","DOI":"10.1183\/13993003.04233-2020"},{"key":"88374_CR20","first-page":"CD013799","volume":"12","author":"Y Oba","year":"2022","unstructured":"Oba, Y., Anwer, S., Maduke, T., Patel, T. & Dias, S. Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: A systematic review and network meta-analysis. Cochrane Database Syst. Rev. 12, CD013799 (2022).","journal-title":"Cochrane Database Syst Rev"},{"key":"88374_CR21","doi-asserted-by":"publisher","first-page":"106934","DOI":"10.1016\/j.rmed.2022.106934","volume":"201","author":"M Orlovic","year":"2022","unstructured":"Orlovic, M., Magni, T., Lukyanov, V., Guerra, I. & Madoni, A. Cost-effectiveness of single-inhaler extrafine beclometasone dipropionate\/formoterol fumarate\/glycopyrronium in patients with uncontrolled asthma in England. Respir. Med. 201, 106934 (2022).","journal-title":"Respir Med"},{"key":"88374_CR22","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1186\/s12890-021-01777-z","volume":"21","author":"JA Buendia","year":"2021","unstructured":"Buendia, J.A. & Patino, D.G. Cost-utility of triple versus dual inhaler therapy in moderate to severe asthma. BMC Pulm. Med. 21, 398 (2021).","journal-title":"BMC Pulm Med"},{"key":"88374_CR23","unstructured":"GSK. Trelegy Ellipta receives positive CHMP opinion supporting expanded COPD indication in Europe. (2018)."},{"key":"88374_CR24","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G. & Group, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 6, e1000097 (2009).","journal-title":"PLoS Med"},{"key":"88374_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher, D., et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst. Rev. 4, 1 (2015).","journal-title":"Syst Rev"},{"key":"88374_CR26","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1080\/02763860802368142","volume":"27","author":"M FitzSimmons","year":"2008","unstructured":"FitzSimmons, M. & Gross, V.A. A review of the OvidSP platform. Med. Ref. Serv. Q 27, 394\u2013405 (2008).","journal-title":"Med Ref Serv Q"},{"key":"88374_CR27","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins, J.P., et al. The Cochrane collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ 343, d5928 (2011).","journal-title":"BMJ"},{"key":"88374_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/1741-7015-12-93","volume":"12","author":"S Cope","year":"2014","unstructured":"Cope, S., et al. A process for assessing the feasibility of a network meta-analysis: A case study of everolimus in combination with hormonal therapy versus chemotherapy for advanced breast cancer. BMC Med. 12, 93 (2014).","journal-title":"BMC Med"},{"key":"88374_CR29","doi-asserted-by":"crossref","unstructured":"Dias, S., Ades, A.E., Welton, N.J., Jansen, J.P. & Sutton, A.J. Network Meta-Analysis for Decision-Making, (Wiley, 2018).","DOI":"10.1002\/9781118951651"},{"key":"88374_CR30","unstructured":"Dias, S., Welton, N.J., Sutton, A.J. & Ades, A.E. NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials. (ed. (NICE), N.I.f.H.a.C.E.) 98 (National Institute for Health and Clinical Excellence (NICE), 2011)."},{"key":"88374_CR31","doi-asserted-by":"crossref","unstructured":"Phillippo, D.M. multinma: An R package for Bayesian network meta-analysis of individual and aggregate data. in Evidence Synthesis and Meta-Analysis in R Conference 2021 (2021).","DOI":"10.32614\/CRAN.package.multinma"},{"key":"88374_CR32","doi-asserted-by":"crossref","unstructured":"Carpenter, B., et al. Stan: A probabilistic programming language. J. Stat. Softw. 76(2017).","DOI":"10.18637\/jss.v076.i01"},{"key":"88374_CR33","unstructured":"Team, R.C. R: A Language and Environment for Statistical Computing. (ed. Vienna) (2013)."},{"key":"88374_CR34","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/jae.1278","volume":"27","author":"JS Racine","year":"2012","unstructured":"Racine, J.S. RStudio: A platform-independent IDE for R and Sweave. J. Appl. Economet, JSTOR 27, 167\u2013172 (2012).","journal-title":"Journal of Applied Econometrics, JSTOR"},{"key":"88374_CR35","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1214\/20-BA1221","volume":"16","author":"A Vehtari","year":"2021","unstructured":"Vehtari, A., Gelman, A., Simpson, D., Carpenter, B. & B\u00fcrkner, P.C. Rank-Normalization, folding, and localization: An improved R for assessing convergence of MCMC (with discussion). Bayesian Anal. 16, 667\u2013718 (2021).","journal-title":"Bayesian Analysis"},{"key":"88374_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1111\/1467-9868.00353","volume":"64","author":"DJ Spiegelhalter","year":"2002","unstructured":"Spiegelhalter, D.J., Best, N.G., Carlin, B.P. & Van Der Linde, A. Bayesian measures of model complexity and fit. J. R. Stat. Soc. Series B Stat. Methodol. 64, 583\u2013639 (2002).","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"88374_CR37","unstructured":"Dias, S., et al. NICE DSU Technical Support document 4: Inconsistency in networks of evidence based on randomised controlled trials. (ed. (NICE), N.I.f.H.a.C.E.) 41 (National Institute for Health and Clinical Excellence (NICE), 2011)."},{"key":"88374_CR38","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","volume":"8","author":"A Chaimani","year":"2013","unstructured":"Chaimani, A., Higgins, J.P.T., Mavridis, D., Spyridonos, P. & Salanti, G. Graphical tools for network meta-analysis in STATA. PLoS One 8, e76654 (2013).","journal-title":"PLoS One"},{"key":"88374_CR39","first-page":"382","volume":"34","author":"YS Lee","year":"2011","unstructured":"Lee, Y.S., et al. Efficacy and tolerability of salmeterol\/fluticasone propionate versus fluticasone propionate in asthma patients: A randomized, double-blind study. Chang Gung Med. J. 34, 382\u2013394 (2011).","journal-title":"Chang Gung Med J"},{"key":"88374_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.clinthera.2005.03.006","volume":"27","author":"JM FitzGerald","year":"2005","unstructured":"FitzGerald, J.M., Boulet, L.P. & Follows, R.M. The CONCEPT trial: A 1-year, multicenter, randomized,double-blind, double-dummy comparison of a stable dosing regimen of salmeterol\/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol\/budesonide in adults with persistent asthma. Clin. Ther. 27, 393\u2013406 (2005).","journal-title":"Clin Ther"},{"key":"88374_CR41","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1183\/09031936.99.14510389","volume":"14","author":"EF Juniper","year":"1999","unstructured":"Juniper, E.F., et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur. Respir. J. 14, 1038\u20131043 (1999).","journal-title":"Eur Respir J"},{"key":"88374_CR42","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.anai.2015.11.011","volume":"116","author":"W Quezada","year":"2016","unstructured":"Quezada, W., et al. Predictors of asthma exacerbation among patients with poorly controlled asthma despite inhaled corticosteroid treatment. Ann. Allergy Asthma Immunol. 116, 112\u2013117 (2016).","journal-title":"Ann Allergy Asthma Immunol"},{"key":"88374_CR43","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1111\/j.1440-1843.2011.01967.x","volume":"16","author":"K Kurashima","year":"2011","unstructured":"Kurashima, K., Kagiyama, N., Takayanagi, N. & Sugita, Y. Comparison of high-dose salmeterol\/fluticasone and moderate-dose salmeterol\/fluticasone plus low-dose mometasone in patients with severe persistent asthma. Respirology 16, 784\u2013789 (2011).","journal-title":"Respirology"},{"key":"88374_CR44","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/BF03256655","volume":"2","author":"ED Bateman","year":"2003","unstructured":"Bateman, E.D., et al. Combination therapy with single inhaler budesonide\/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma. Am. J. Respir. Med. 2, 275\u2013281 (2003).","journal-title":"Am J Respir Med"},{"key":"88374_CR45","first-page":"50","volume":"134","author":"KC Bergmann","year":"2004","unstructured":"Bergmann, K.C., Lindemann, L., Braun, R. & Steinkamp, G. Salmeterol\/fluticasone propionate (50\/250 microg) combination is superior to double dose fluticasone (500 microg) for the treatment of symptomatic moderate asthma. Swiss Med. Wkly. 134, 50\u201358 (2004).","journal-title":"Swiss Med Wkly"},{"key":"88374_CR46","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.rmed.2010.11.011","volume":"105","author":"A Bodzenta-Lukaszyk","year":"2011","unstructured":"Bodzenta-Lukaszyk, A., et al. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir. Med. 105, 674\u2013682 (2011).","journal-title":"Respir Med"},{"key":"88374_CR47","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1034\/j.1399-3003.1999.14c24.x","volume":"14","author":"D Bouros","year":"1999","unstructured":"Bouros, D., et al. Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma. Eur. Respir. J. 14, 627\u2013632 (1999).","journal-title":"Eur Respir J"},{"key":"88374_CR48","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1053\/rmed.2002.1427","volume":"97","author":"R Buhl","year":"2003","unstructured":"Buhl, R., et al. Once-daily budesonide\/formoterol in a single inhaler in adults with moderate persistent asthma. Respir. Med. 97, 323\u2013330 (2003).","journal-title":"Respir Med"},{"key":"88374_CR49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0140-6736(94)92996-3","volume":"344","author":"AP Greening","year":"1994","unstructured":"Greening, A.P., Ind, P.W., Northfield, M. & Shaw, G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys limited UK study group. Lancet 344, 219\u2013224 (1994).","journal-title":"Lancet"},{"key":"88374_CR50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.rmed.2008.09.002","volume":"103","author":"G Huchon","year":"2009","unstructured":"Huchon, G., et al. Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir. Med. 103, 41\u201349 (2009).","journal-title":"Respir Med"},{"key":"88374_CR51","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/j.rmed.2006.03.016","volume":"100","author":"P Kuna","year":"2006","unstructured":"Kuna, P., et al. Once-daily dosing with budesonide\/formoterol compared with twice-daily budesonide\/formoterol and once-daily budesonide in adults with mild to moderate asthma. Respir. Med. 100, 2151\u20132159 (2006).","journal-title":"Respir Med"},{"key":"88374_CR52","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1016\/j.rmed.2008.04.022","volume":"102","author":"MB Menezes","year":"2008","unstructured":"Menezes, M.B., Teixeira, A.L., Terra Filho, J. & Vianna, E.O. Inflammatory and functional effects of increasing asthma treatment with formoterol or double dose budesonide. Respir. Med. 102, 1385\u20131391 (2008).","journal-title":"Respir Med"},{"key":"88374_CR53","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/S1094-5539(03)00071-3","volume":"16","author":"C Mitchell","year":"2003","unstructured":"Mitchell, C., Jenkins, C., Scicchitano, R., Rubinfeld, A. & Kottakis, J. Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma. Pulm Pharmacol. Ther. 16, 299\u2013306 (2003).","journal-title":"Pulm Pharmacol Ther"},{"key":"88374_CR54","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12890-016-0335-9","volume":"16","author":"P Paggiaro","year":"2016","unstructured":"Paggiaro, P., et al. High strength extrafine pMDI beclometasone\/formoterol (200\/6 mug) is effective in asthma patients not adequately controlled on medium-high dose of inhaled corticosteroids. BMC Pulm. Med. 16, 180 (2016).","journal-title":"BMC Pulm Med"},{"key":"88374_CR55","doi-asserted-by":"publisher","first-page":"272","DOI":"10.4103\/0970-2113.180803","volume":"33","author":"SS Salvi","year":"2016","unstructured":"Salvi, S.S., Vaidya, A.J., Kodgule, R.R. & Gogtay, J.A. A randomized, double-blind study comparing the efficacy and safety of a combination of formoterol and ciclesonide with ciclesonide alone in asthma subjects with moderate-to-severe airflow limitation. Lung India 33, 272\u2013277 (2016).","journal-title":"Lung India"},{"key":"88374_CR56","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1590\/S1806-37132012000400004","volume":"38","author":"R Stirbulov","year":"2012","unstructured":"Stirbulov, R., Fritscher, C.C., Pizzichini, E. & Pizzichini, M.M. Evaluation of the efficacy and safety of a fixed-dose, single-capsule budesonide-formoterol combination in uncontrolled asthma: A randomized, double-blind, multicenter, controlled clinical trial. J. Bras. Pneumol. 38, 431\u2013437 (2012).","journal-title":"J Bras Pneumol"},{"key":"88374_CR57","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.rmed.2004.03.004","volume":"98","author":"AM Strand","year":"2004","unstructured":"Strand, A.M., Luckow, A. & Danish, I.f.A.t. initiation of maintenance treatment of persistent asthma: Salmeterol\/fluticasone propionate combination treatment is more effective than inhaled steroid alone. Respir. Med. 98, 1008\u20131015 (2004).","journal-title":"Respir Med"},{"key":"88374_CR58","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1067\/mai.2003.1518","volume":"112","author":"A Wallin","year":"2003","unstructured":"Wallin, A., et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J. Allergy Clin. Immunol. 112, 72\u201378 (2003).","journal-title":"J Allergy Clin Immunol"},{"key":"88374_CR59","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1183\/09031936.01.00065801","volume":"18","author":"O Zetterstrom","year":"2001","unstructured":"Zetterstrom, O., et al. Improved asthma control with budesonide\/formoterol in a single inhaler, compared with budesonide alone. Eur. Respir. J. 18, 262\u2013268 (2001).","journal-title":"Eur Respir J"},{"key":"88374_CR60","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1183\/09031936.00022010","volume":"36","author":"M Aubier","year":"2010","unstructured":"Aubier, M., et al. Comparison of two twice-daily doses of budesonide\/formoterol maintenance and reliever therapy. Eur. Respir. J. 36, 524\u2013530 (2010).","journal-title":"Eur Respir J"},{"key":"88374_CR61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.pupt.2017.09.001","volume":"48","author":"A Balki","year":"2018","unstructured":"Balki, A., et al. Comparison of fluticasone\/formoterol with budesonide\/formoterol pMDI in adults with moderate to severe persistent asthma: Results from a 12-week randomized controlled trial. Pulm. Pharmacol. Ther. 48, 28\u201336 (2018).","journal-title":"Pulm Pharmacol Ther"},{"key":"88374_CR62","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.jfma.2017.12.005","volume":"117","author":"MJ Hsieh","year":"2018","unstructured":"Hsieh, M.J., et al. Comparative efficacy and tolerability of beclomethasone\/formoterol and fluticasone\/salmeterol fixed combination in Taiwanese asthmatic patients. J. Formos. Med. Assoc. 117, 1078\u20131085 (2018).","journal-title":"J Formos Med Assoc"},{"key":"88374_CR63","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S2213-2600(13)70012-2","volume":"1","author":"A Papi","year":"2013","unstructured":"Papi, A., et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: A double-blind, randomised controlled trial. Lancet Respir Med 1, 23\u201331 (2013).","journal-title":"Lancet Respir Med"},{"key":"88374_CR64","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1111\/j.1398-9995.2007.01493.x","volume":"62","author":"A Papi","year":"2007","unstructured":"Papi, A., et al. Beclomethasone\/formoterol vs fluticasone\/salmeterol inhaled combination in moderate to severe asthma. Allergy 62, 1182\u20131188 (2007).","journal-title":"Allergy"},{"key":"88374_CR65","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1183\/09031936.00095906","volume":"29","author":"A Papi","year":"2007","unstructured":"Papi, A., et al. Beclomethasone\/formoterol versus budesonide\/formoterol combination therapy in asthma. Eur. Respir. J. 29, 682\u2013689 (2007).","journal-title":"Eur Respir J"},{"key":"88374_CR66","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/j.1368-5031.2005.00474.x","volume":"59","author":"L You-Ning","year":"2005","unstructured":"You-Ning, L., Humphries, M., Du, X., Wang, L. & Jiang, J. Efficacy and safety of salmeterol\/fluticasone propionate delivered via a hydrofluoroalkane metered dose inhaler in Chinese patients with moderate asthma poorly controlled with inhaled corticosteroids. Int. J. Clin. Pract. 59, 754\u2013759 (2005).","journal-title":"Int J Clin Pract"},{"key":"88374_CR67","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12890-017-0409-3","volume":"17","author":"RY Suruki","year":"2017","unstructured":"Suruki, R.Y., Daugherty, J.B., Boudiaf, N. & Albers, F.C. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 17, 74 (2017).","journal-title":"BMC Pulm Med"},{"key":"88374_CR68","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1164\/rccm.201810-1868CI","volume":"199","author":"R Beasley","year":"2019","unstructured":"Beasley, R., et al. Inhaled corticosteroid therapy in adult asthma. Time for a new therapeutic dose terminology. Am. J. Respir. Crit. Care Med. 199, 1471\u20131477 (2019).","journal-title":"Am J Respir Crit Care Med"},{"key":"88374_CR69","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jaip.2018.01.025","volume":"6","author":"E Heffler","year":"2018","unstructured":"Heffler, E., et al. Inhaled corticosteroids Safety and adverse effects in patients with asthma. J. Allergy Clin. Immunol. Pract. 6, 776\u2013781 (2018).","journal-title":"J Allergy Clin Immunol Pract"},{"key":"88374_CR70","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1210\/jc.2015-1218","volume":"100","author":"LH Broersen","year":"2015","unstructured":"Broersen, L.H., Pereira, A.M., Jorgensen, J.O. & Dekkers, O.M. Adrenal insufficiency in corticosteroids use: Systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 100, 2171\u20132180 (2015).","journal-title":"J Clin Endocrinol Metab"},{"key":"88374_CR71","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.rmed.2006.03.001","volume":"100","author":"R Dahl","year":"2006","unstructured":"Dahl, R., Chuchalin, A., Gor, D., Yoxall, S. & Sharma, R. EXCEL: A randomised trial comparing salmeterol\/fluticasone propionate and formoterol\/budesonide combinations in adults with persistent asthma. Respir. Med. 100, 1152\u20131162 (2006).","journal-title":"Respir Med"},{"key":"88374_CR72","doi-asserted-by":"crossref","unstructured":"Singh, D., et al. Extrafine triple therapy in patients with asthma and persistent airflow limitation. Eur. Respir. J. 56(2020).","DOI":"10.1183\/13993003.00476-2020"},{"key":"88374_CR73","doi-asserted-by":"publisher","first-page":"107172","DOI":"10.1016\/j.rmed.2023.107172","volume":"211","author":"RN Van Zyl-Smit","year":"2023","unstructured":"Van Zyl-Smit, R.N., et al. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone\/indacaterol\/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study. Respir. Med. 211, 107172 (2023).","journal-title":"Respir Med"},{"key":"88374_CR74","doi-asserted-by":"publisher","first-page":"2904","DOI":"10.1016\/j.jaip.2022.06.010","volume":"10","author":"WW Busse","year":"2022","unstructured":"Busse, W.W., et al. Adherence and persistence to single-inhaler Versus multiple-inhaler Triple Therapy for Asthma Management. J. Allergy Clin. Immunol. Pract. 10, 2904\u20132913.e2906 (2022).","journal-title":"J Allergy Clin Immunol Pract"},{"key":"88374_CR75","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.2147\/COPD.S370540","volume":"17","author":"DMG Halpin","year":"2022","unstructured":"Halpin, D.M.G., et al. Comparative adherence and persistence of single- and multiple-inhaler triple therapies among patients with chronic obstructive pulmonary disease in an english real-world primary care setting. Int. J. Chron. Obstruct. Pulmon. Dis. 17, 2417\u20132429 (2022).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"88374_CR76","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1016\/j.rmed.2013.04.005","volume":"107","author":"MJ M\u00e4kel\u00e4","year":"2013","unstructured":"M\u00e4kel\u00e4, M.J., Backer, V., Hedegaard, M. & Larsson, K. Adherence to inhaled therapies, health outcomes and costs in patients with asthma and COPD. Respir. Med. 107, 1481\u20131490 (2013).","journal-title":"Respir Med"},{"key":"88374_CR77","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S2213-2600(14)70103-1","volume":"2","author":"B Lipworth","year":"2014","unstructured":"Lipworth, B., Manoharan, A. & Anderson, W. Unlocking the quiet zone: The small airway asthma phenotype. Lancet. Respir. Med. 2, 497\u2013506 (2014).","journal-title":"Lancet Respir. Med."},{"key":"88374_CR78","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/S2213-2600(19)30049-9","volume":"7","author":"DS Postma","year":"2019","unstructured":"Postma, D.S., et al. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): Baseline data from a prospective cohort study. Lancet Respir. Med. 7, 402\u2013416 (2019).","journal-title":"The Lancet Respiratory Medicine"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88374-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88374-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T04:28:17Z","timestamp":1738643297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-88374-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,4]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["88374"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-88374-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,4]]},"assertion":[{"value":"29 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Ethics approval was not obtained because this study did not involve human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Patients and members of the public were not specifically involved in the design, conduct, and reporting of this research. Nevertheless, the research questions answered in this study is of broad public health and decision-making interest, and results will be disseminated to the general public through websites, public engagement events, and conferences.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}}],"article-number":"4191"}}